The Japan presidents of foreign pharma companies are no longer hiding their concerns about the stagnation of drug development in the Japanese market. In their business briefings for 2021, many of them made explicit criticism against what they see as…
HOME > ACADEMIA
ACADEMIA
- Oncologist Hails Tagrisso Approval for 1st-Line Lung Cancer Treatment
September 14, 2018
- Japan Cancer Association to Release Statement on Health Spending at Sept. Meeting
August 24, 2018
- Only 30% of Patients Took Thyroid Tests before Receiving Dementia Meds: Survey
July 25, 2018
- Debut of siRNA Therapeutic Looming on Horizon; Alnylam’s Patisiran Might Be Filed in Japan Too
July 24, 2018
- Japanese Society of Medical Oncology to Update I/O Guidelines in October
July 18, 2018
- Hematologist Optimistic about New Drugs for AML Including SMO and BCL-2 Inhibitors as Well as FLT3 Inhibitors
July 11, 2018
- Doctors Need Solid Understanding of Hereditary Cancer When Prescribing Lynparza for Breast Cancer: Prof.
July 5, 2018
- Anti-TNF-α Antibody Treatment for Crohn’s Disease Costs 1.95 Million Yen per Patient Annually: Study
June 27, 2018
- Licensee Selection Draws Near for AMED-Backed Cancer Mouth Sores Treatment
June 26, 2018
- Nucala, Fasenra to Be Ranked as Strongest Treatments in New Asthma Guidelines: Allergology Society
June 21, 2018
- MHLW Study Group to Discuss Roles of JAK Inhibitors and Biosimilars toward RA Treatment Guidelines Revision
June 5, 2018
- Nephrology Society to Issue New CKD Guidelines; Recommends Less-Strict Blood Pressure Management Target
June 4, 2018
- AZ’s Durvalumab to Become New Treatment Option for Stage III NSCL Cancer: Oncologist
May 28, 2018
- Breast Cancer Society Initiates Trial to Evaluate Efficacy of Denosumab at Increasing Bone Mass
May 21, 2018
- Dupixent Used Generally as Adjunctive Therapy to Existing Treatments for Atopic Dermatitis: Dermatologist
May 10, 2018
- 55 Anticancer Meds Available Overseas Unapproved in Japan, 3 Meds Costing over 10 Million Yen Monthly: NCC
May 2, 2018
- New Guidelines Recommend LAMA as First-Line Bronchodilator for COPD: Respiratory Society
April 24, 2018
- Clinical Trials for Mitochondrial Disease Heating Up with AMED’s Support; Filing for First Hyperlactacidemia Drug Expected in 2020
April 23, 2018
- Expert Cautions against Hasty Discussions on Cost Effective Assessments
April 20, 2018
- Biosimilar Use Essential to Sustain Universal Health Coverage: Society President
April 19, 2018
ページ
The missing ingredient for managers is not their skill, ability, or education. Academic achievements and business success will get runs on the board, to a certain level. However, that is just half of the story.Leaders come in all shapes and…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…